From Policing to Proactive: Mastering the FDAs New Risk Based Mandate for Medical Devices
With the FDAs recent shift from QSR to QMSR, the expectation for medical device manufacturers is that risk is no longer focused on just R&D design phase activities; rather companies need to adopt risk-based thinking throughout all quality management system elements. The new inspection model states that one of the goals of FDA inspections for medical device manufacturers is to evaluate “risk management and risk-based decision making are effectively used in the QMS”. By focusing inspection resources, data collection, and corrective actions on areas with the greatest potential for harm, the FDA aims to improve patient safety, promote efficient use of regulatory resources, and encourage innovation without compromising protection. Risk must be managed through an integrated, risk-based approach that spans the entire manufacturing lifecycle. In the new FDA inspection model, compliance is the byproduct of a mature risk-based culture. So, what does a system wide risk-based approach look like? Let’s explore this in more detail.
To begin, let’s turn to the FDAs new inspection model which has shifted from QSIT to CP7382.850. The risk-based inspection process evaluates related requirements with a focus on risks to the patient and/or user. The risk-based inspection process organizes the QMSR requirements into 6 areas. In each area, the organization should consider how risk-based decision making can be adopted and integrated into standard workflows.
Management Oversight
Management oversight is critical to effective risk-based thinking. A trend in FDA enforcement actions including warning letters gives us a picture of how important management oversight is to overall FDA compliance. These warning letters signal the result of systemic failures in a company's Quality Management System, with management oversight appearing as a critical recurring theme in recent enforcement actions. To avoid this, leadership must set measurable quality objectives, and ensure resources and competence are available to identify, assess, control, and monitor risks across the product lifecycle. The management review processes should be systematic and evidence-based, using data from CAPA, post-market surveillance, supplier performance, and process controls to prioritize actions and verify effectiveness. Senior management must also ensure alignment between business strategy and quality objectives, drive continuous improvement, and maintain regulatory readiness.
Production and Service Provision
Production and service provision within a Quality Management System include all activities surround product realization. Organizations should evaluate these workflows to assure they meet the FDA’s risk-based directive for medical devices which emphasize proactive identification, control, and mitigation of risks across manufacturing and service activities. This includes integrating risk assessment into process design, establishing controls for critical production parameters, validating and monitoring suppliers and outsourced processes based on their risk impact, and implementing robust nonconformance handling that prioritizes patient safety and device performance. Risks arise from equipment failure, lack of repeatability across lots or inadequate process validation. Environmental factors such as temperature, humidity and cleanliness (cleanrooms) are critical for preventing biological contamination or material degradation.
Production training systems should move away from read and understand modality and instead should be competency-based demonstrating staff can perform critical manufacturing tasks accurately and consistently. The amount of training resources should be commensurate with the level of risk for the task. Additionally, service provision (installation, maintenance, servicing) requires risk-based service instructions, remote and onsite verification controls, and feedback loops that feed post-market surveillance and CAPA to continuously reduce residual risk throughout the product lifecycle. Post market data such as complaints, MDRs and service reports should be analyzed routinely to assess any impact to the original risk file looking for any changes in severity or probability.
Design and Development
In the design and development of a medical device QMS, FDA expectations emphasize risk-based thinking as a continuous, documented process that informs decisions from concept through transfer to production. Medical device designers must identify hazards, estimate and evaluate associated risks, implement and verify risk controls (including design mitigations and verification/validation activities), and assess residual risk versus intended benefits while maintaining traceability of risk decisions.
Change Control
Effective change control in the medical device industry integrates FDA expectations with risk-based thinking to ensure that modifications to design, processes, materials, suppliers, or labeling do not adversely affect the safety or performance of the device. Organizations should perform risk assessments (including impact on device form, fit, function, and validation) to determine appropriate levels of verification and validation, and document formal cross functional approvals. Applying a proactive, science and risk-based approach to change control reduces regulatory and patient-safety risk to ensure continued device safety and effectiveness throughout the product lifecycle.
Outsourcing and Purchasing
Outsourcing and purchasing in the FDA medical device industry are integral to risk-based decision making because they directly affect the safety, performance, and regulatory compliance of finished devices. Manufacturers must evaluate suppliers’ quality systems and prioritize oversight based on product criticality, supplier performance, and establish contractual requirements, incoming inspection, and ongoing monitoring that align with the assessed level of risk. A risk-based approach enables appropriate audit frequency, acceptance criteria, and corrective action expectations. Recent supply chain disruptions, from raw material shortages to geopolitical shifts and transportation delays, pose significant regulatory, quality, and patient-safety risks for the medical device industry. A risk-based approach to supplier management evaluates the likelihood and severity of failure modes; and applies proportional controls such as increased monitoring, redundancy, qualification audits, and contingency planning. By integrating supply chain risk into design and purchasing controls, manufacturers can protect device quality and continuity of supply while meeting regulatory expectations.
Measurement Analysis and Improvement
Measurement analysis and improvement is important for a risk-based approach to medical device compliance, as they provide objective evidence to identify, quantify, and reduce risks across the product lifecycle. Organizations should establish robust measurement systems, covering process capability, incoming inspection of components, defect rates, nonconformances, and key performance indicators tied to safety and effectiveness. Ongoing analysis using statistical methods and trend evaluation enables prioritization of high-risk areas, root cause identification, and targeted corrective and preventive actions. Continuous improvement efforts (including control plans, design of experiments, and risk control verification) close the loop by verifying that implemented changes reduce risk and sustain compliance with FDA expectations.
In summary, the FDA’s new risk-based requirement marks a shift toward prioritizing resources and oversight where patient safety and device performance are most at risk, compelling manufacturers to adopt formalized risk assessment, mitigation, and monitoring practices across the product lifecycle. By demonstrating a risk-based approach to the six QMSR areas with documented evidence, companies can improve regulatory compliance, reduce preventable harms, and focus continuous improvement efforts on high-impact areas. As a quality practitioner, using a risk-based framework for decision making helps take the guess work out of where to spend time and resources. It’s a practical approach that when supported by the organization and implemented effectively throughout workflows can realize cost efficiencies and increase compliance. Embracing these changes not only meets regulatory obligations but also advances device reliability and patient trust, turning compliance into a strategic advantage.
